<unk> , sold under the brand name Cabenuva, is a co-packaged antiretroviral medication for the treatment of HIV/AIDS. It contains<unk>  and<unk>  in a package with two separate injection vials. The most common adverse reactions include injection site reactions, fever or feeling hot (pyrexia), fatigue, headache, musculoskeletal pain, nausea, sleep disorders, dizziness and rash. The co-packaged medication was approved for medical use in the United States in January 2021. It is the first FDA-approved injectable, complete regimen for HIV-infected adults that is administered once a month. It is also approved for use in Canada. In the European Union, the two drugs are approved separately.
Cabotegravir/rilpivirine
Atazanavir/cobicistat
Atazanavir/ritonavir
Dolutegravir/rilpivirine
Nirmatrelvir/ritonavir
Darunavir/cobicistat
Abacavir/lamivudine
Lamivudine/tenofovir